Haemonetics Stock Price, News & Analysis (NYSE:HAE)

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics declared that its Board of Directors has initiated a stock buyback program on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's board believes its stock is undervalued.

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings data on Tuesday, August, 6th. The medical instruments supplier reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.18. The medical instruments supplier earned $238.50 million during the quarter, compared to the consensus estimate of $236.82 million. Haemonetics had a return on equity of 21.07% and a net margin of 5.05%. The firm's quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 earnings per share. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for Haemonetics.

Haemonetics will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Haemonetics issued an update on its FY20 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $2.95-3.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.94. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.00 billion.

5 Wall Street analysts have issued twelve-month price objectives for Haemonetics' shares. Their forecasts range from $139.00 to $150.00. On average, they anticipate Haemonetics' stock price to reach $144.40 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View Analyst Price Targets for Haemonetics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

Headlines about HAE stock have trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Haemonetics earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Haemonetics.

Haemonetics saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 826,400 shares, a decrease of 13.5% from the August 30th total of 955,900 shares. Based on an average daily trading volume, of 353,700 shares, the short-interest ratio is currently 2.3 days. Approximately 1.6% of the company's stock are sold short. View Haemonetics' Current Options Chain.

Some companies that are related to Haemonetics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Neogen (NEOG), ICU Medical (ICUI), Quidel (QDEL), Merit Medical Systems (MMSI), Atrion (ATRI), STAAR Surgical (STAA), Anika Therapeutics (ANIK), Cerus (CERS), Antares Pharma (ATRS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Apache (APA), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Micron Technology (MU), Adobe (ADBE), NVIDIA (NVDA), Aegean Marine Petroleum Network (ANW) and CA (CA).

Haemonetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (0.23%), Pacer Advisors Inc. (0.04%), Envestnet Asset Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%), Zeke Capital Advisors LLC (0.01%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Baldwin Brothers Inc. MA, Pacer Advisors Inc., First Citizens Bank & Trust Co., Zeke Capital Advisors LLC, Crossmark Global Holdings Inc. and Oakbrook Investments LLC. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Meeder Asset Management Inc., Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, Boston Trust Walden Corp and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $127.25.

Haemonetics has a market capitalization of $6.46 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]